Nuclear medicine is becoming increasingly important in the treatment of prostate cancer, using overexpression of the prostate-specific membrane antigen (PSMA) on the surface of prostate cancer cells to internalise intravenously administered, radiolabelled PSMA ligands for diagnostic and therapeutic purposes [4, 5, 6, 7, 8, 9]. This evidence concerns the gene FOLH1 and Familial prostate cancer.